| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | KMT3C; HSKM-B; ZMYND14 |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SMYD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SMYD2抗体的3篇参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*SMYD2-Mediated p53 Methylation Promotes Tumorigenesis*
**作者**：Huang, J. et al.
**摘要**：该研究通过Western blot和免疫沉淀实验，使用SMYD2抗体证明SMYD2在多种癌细胞中高表达，并通过甲基化p53抑制其转录活性，促进肿瘤发生。抗体特异性验证显示其对SMYD2的高亲和力。
2. **文献名称**：*SMYD2 Drives Cancer Cell Metastasis via Histone H3K36 Methylation*
**作者**：Ferguson, D. et al.
**摘要**：研究利用SMYD2抗体进行免疫组织化学(IHC)分析，发现SMYD2在乳腺癌组织中的高表达与患者预后不良相关。体外实验进一步表明SMYD2通过甲基化组蛋白H3K36调控促转移基因表达。
3. **文献名称**：*Targeting SMYD2 in Cancer Therapy: Antibody Validation and Functional Studies*
**作者**：Sakamoto, K. et al.
**摘要**：该文献系统验证了多种SMYD2抗体的特异性，并筛选出适用于ChIP-seq的抗体。研究发现SMYD2通过甲基化非组蛋白底物(如ERα)调控癌症细胞增殖，为靶向治疗提供依据。
---
以上文献均涉及SMYD2抗体的应用，涵盖肿瘤机制、临床相关性及抗体特异性验证方向。如需具体期刊或年份信息，可进一步补充数据库检索结果。
SMYD2 (SET and MYND domain-containing protein 2) is a lysine methyltransferase that plays a critical role in epigenetic regulation and post-translational modification of proteins. It catalyzes the methylation of histone H3 at lysine 4 (H3K4) and lysine 36 (H3K36), as well as non-histone targets like p53. RB, and HSP90. influencing processes such as gene transcription, cell cycle progression, and apoptosis. SMYD2 is implicated in various cancers, where its overexpression often correlates with tumor growth, metastasis, and poor prognosis. For instance, it methylates p53 at K370. repressing its tumor-suppressor activity.
SMYD2-specific antibodies are essential tools for studying its expression, localization, and functional interactions. These antibodies enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in research on SMYD2’s role in diseases. They also support chromatin immunoprecipitation (ChIP) assays to identify SMYD2-binding genomic regions. Commercially available antibodies vary in specificity, with validation often performed using knockout cell lines or peptide competition assays. Recent studies highlight SMYD2 as a therapeutic target, driving demand for reliable antibodies to evaluate inhibitors in preclinical models. However, cross-reactivity with other SMYD family members remains a challenge, underscoring the need for rigorously validated reagents.
×
